Cadila Healthcare Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cadila Healthcare Ltd. - overview
Established
1952
Location
Ahmedabad, Gujarat, India
Primary Industry
Pharmaceuticals
About
Cadila Healthcare Ltd. specializes in the development and manufacturing of a diverse range of pharmaceuticals, including innovative vaccines and biosimilars, showcasing its commitment to global health solutions. Founded in 1952, Cadila Healthcare Ltd. operates primarily from its headquarters in Ahmedabad, India.
The company has pivoted to focus on innovative healthcare products and has made strategic moves into global markets. Notably, it has received investment through a PIPE round amounting to USD 16. 00 mn, led by ChrysCapital. The latest funding round brought its total amount raised to USD 16.
00 mn over two deals. Cadila Healthcare Ltd. offers an extensive portfolio of pharmaceuticals, including formulations, active pharmaceutical ingredients (APIs), biosimilars, and vaccines. The company is noted for the development of pioneering medical solutions such as the world's first rabies monoclonal antibodies cocktail, designed for dual protection against the disease.
Additionally, it is active in developing new chemical entities and vaccines for common illnesses like influenza, which targets four major virus types. Cadila's products are distributed across both regulated and emerging markets, reaching a wide range of healthcare providers and patients. For the year 2023, Cadila Healthcare Ltd. reported revenue from operations amounting to USD 2,147.
76 mn. The company generates revenue through B2B partnerships, direct sales to healthcare facilities, and distribution agreements with various wholesalers and retailers, ensuring steady cash flow from the sale of its pharmaceutical offerings. Cadila Healthcare Ltd. is focused on launching new products in the near future, including innovative vaccines and treatments targeted at global health challenges.
The company plans to expand into new geographic markets, particularly in regions like Latin America and South Africa, by the end of the next fiscal year. The recent PIPE funding of USD 16. 00 mn will be instrumental in supporting these initiatives, although specifics related to the exact allocation of funds were not disclosed following ChrysCapital's exit from its stake in the company.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.zyduscadila.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Cadila Healthcare Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Animal Healthcare Established Markets Undertaking | - | ||||||||
| Add-on | Completed | The consumer food division of Kraft Heinz Co. in India | - | ||||||||
| PIPE | Completed | Zydus Wellness Ltd | - | ||||||||
| Trade Sale | Completed | Windlas Biotech Limited | - | ||||||||
| N/A | Completed | 1016 16th Street | - |
Displaying 1 - 5 of 7
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.